Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 3
1982 2
1983 5
1984 1
1985 4
1986 9
1987 6
1988 12
1989 24
1990 23
1991 30
1992 27
1993 42
1994 42
1995 40
1996 40
1997 41
1998 49
1999 59
2000 57
2001 75
2002 59
2003 58
2004 76
2005 79
2006 100
2007 103
2008 112
2009 107
2010 140
2011 146
2012 145
2013 155
2014 152
2015 161
2016 170
2017 161
2018 153
2019 151
2020 164
2021 192
2022 159
2023 167
2024 182
2025 233
2026 172

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,673 results

Results by year

Filters applied: . Clear all
Page 1
ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk.
Sehayek D, Cole J, Björnson E, Wilkins JT, Mortensen MB, Dufresne L, Pencina KM, Pencina MJ, Thanassoulis G, Sniderman AD. Sehayek D, et al. J Clin Lipidol. 2025 Jul-Aug;19(4):844-859. doi: 10.1016/j.jacl.2025.05.024. Epub 2025 Jun 6. J Clin Lipidol. 2025. PMID: 40681368
OBJECTIVE: This systematic review compiled all discordance studies that compare the predictive powers of LDL-C and non-HDL-C vs LDL particle number (LDL P) or apoB as markers of atherosclerotic disease risk to determine which is the most accurate marker of …
OBJECTIVE: This systematic review compiled all discordance studies that compare the predictive powers of LDL-C and non-HDL-C vs LDL particle …
Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association.
Soffer DE, Marston NA, Maki KC, Jacobson TA, Bittner VA, Peña JM, Thanassoulis G, Martin SS, Kirkpatrick CF, Virani SS, Dixon DL, Ballantyne CM, Remaley AT. Soffer DE, et al. J Clin Lipidol. 2024 Sep-Oct;18(5):e647-e663. doi: 10.1016/j.jacl.2024.08.013. Epub 2024 Sep 5. J Clin Lipidol. 2024. PMID: 39256087 Free PMC article.
ApoB has been shown to be superior to LDL-C in risk assessment both before and during treatment with LLT. ...When there is discordance between LDL-C and apoB, or LDL-C and non-HDL-C, atherosclerotic cardiovascular disease risk generally a …
ApoB has been shown to be superior to LDL-C in risk assessment both before and during treatment with LLT. ...When there is dis …
Excess Apolipoprotein B and Cardiovascular Risk in Women and Men.
Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Johannesen CDL, et al. J Am Coll Cardiol. 2024 Jun 11;83(23):2262-2273. doi: 10.1016/j.jacc.2024.03.423. J Am Coll Cardiol. 2024. PMID: 38839200 Free article.
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) are highly correlated measures of atherogenic lipoproteins. OBJECTIVES: The study investigators hypothesized that excess apoB is associated with an increased risk of myocardia …
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) are highly correlated measures of atherogenic lip …
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, Murphy SA, Goodrich EL, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano RP, Sabatine MS; Bridge–TIMI 73a Investigators. Bergmark BA, et al. N Engl J Med. 2024 May 16;390(19):1770-1780. doi: 10.1056/NEJMoa2402309. Epub 2024 Apr 7. N Engl J Med. 2024. PMID: 38587249 Clinical Trial.
METHODS: In this phase 2b, randomized, controlled trial, we assigned adults either with moderate hypertriglyceridemia (triglyceride level, 150 to 499 mg per deciliter) and elevated cardiovascular risk or with severe hypertriglyceridemia (triglyceride level, 500 mg …
METHODS: In this phase 2b, randomized, controlled trial, we assigned adults either with moderate hypertriglyceridemia (triglyceride level, 1 …
Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice.
De Oliveira-Gomes D, Joshi PH, Peterson ED, Rohatgi A, Khera A, Navar AM. De Oliveira-Gomes D, et al. Circulation. 2024 Jul 2;150(1):62-79. doi: 10.1161/CIRCULATIONAHA.124.068885. Epub 2024 Jul 1. Circulation. 2024. PMID: 38950110 Free PMC article. Review.
Despite data suggesting that apolipoprotein B (apoB) measurement outperforms low-density lipoprotein cholesterol level measurement in predicting atherosclerotic cardiovascular disease risk, apoB measurement has not become widely adopted into rou …
Despite data suggesting that apolipoprotein B (apoB) measurement outperforms low-density lipoprotein cholesterol level measurement in …
Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk.
Glavinovic T, Thanassoulis G, de Graaf J, Couture P, Hegele RA, Sniderman AD. Glavinovic T, et al. J Am Heart Assoc. 2022 Oct 18;11(20):e025858. doi: 10.1161/JAHA.122.025858. Epub 2022 Oct 10. J Am Heart Assoc. 2022. PMID: 36216435 Free PMC article. Review.
Since then, the evidence has continued to mount in favor of apoB. This review explicates the physiological mechanisms responsible for the superiority of apoB as a marker of the cardiovascular risk attributable to the atherogenic apoB lipoprotein …
Since then, the evidence has continued to mount in favor of apoB. This review explicates the physiological mechanisms responsible for …
Oxidized phospholipids in cardiovascular disease.
Tsimikas S, Witztum JL. Tsimikas S, et al. Nat Rev Cardiol. 2024 Mar;21(3):170-191. doi: 10.1038/s41569-023-00937-4. Epub 2023 Oct 17. Nat Rev Cardiol. 2024. PMID: 37848630 Review.
The addition of OxPL-apoB measurements to traditional cardiovascular risk factors improves risk reclassification, particularly in patients in intermediate risk categories, for whom improving decision-making is most impactful. Moreover, pl …
The addition of OxPL-apoB measurements to traditional cardiovascular risk factors improves risk reclassif …
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.
Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, Lima J, Puri R, Nomura S, Tsai M, Wilkins J, Ballantyne CM, Nicholls S, Jones SR, Elshazly MB. Quispe R, et al. Eur Heart J. 2021 Nov 7;42(42):4324-4332. doi: 10.1093/eurheartj/ehab432. Eur Heart J. 2021. PMID: 34293083 Free PMC article.
AIMS: Emerging evidence suggests that remnant cholesterol (RC) promotes atherosclerotic cardiovascular disease (ASCVD). We aimed to estimate RC-related risk beyond low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) in patients with …
AIMS: Emerging evidence suggests that remnant cholesterol (RC) promotes atherosclerotic cardiovascular disease (ASCVD). We aim …
Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention.
Sniderman AD, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G, Pencina MJ. Sniderman AD, et al. Eur Heart J. 2024 Jul 12;45(27):2410-2418. doi: 10.1093/eurheartj/ehae258. Eur Heart J. 2024. PMID: 38700053 Free PMC article.
BACKGROUND AND AIMS: Despite growing evidence that apolipoprotein B (apoB) is the most accurate marker of atherosclerotic cardiovascular disease (ASCVD) risk, its adoption in clinical practice has been low. ...Residuals of apoB were constructed …
BACKGROUND AND AIMS: Despite growing evidence that apolipoprotein B (apoB) is the most accurate marker of atherosclerotic cardiova …
ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease.
Morze J, Melloni GEM, Wittenbecher C, Ala-Korpela M, Rynkiewicz A, Guasch-Ferré M, Ruff CT, Hu FB, Sabatine MS, Marston NA. Morze J, et al. Eur Heart J. 2025 Jul 14;46(27):2691-2701. doi: 10.1093/eurheartj/ehaf207. Eur Heart J. 2025. PMID: 40289348 Free article.
BACKGROUND AND AIMS: Apolipoprotein B concentration reflects the number of atherogenic lipoproteins and is recognized as a key lipid risk marker. Whether the type or size of apoB particle (apoB-P) adds predictive value for coronary artery disease (CAD) …
BACKGROUND AND AIMS: Apolipoprotein B concentration reflects the number of atherogenic lipoproteins and is recognized as a key lipid risk …
3,673 results